In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Xalkori And The Art Of Modern Drug Development

Executive Summary

Pfizer developed crizotinib and its companion diagnostic in just four years after identifying an aberrant ALK gene as the target, spanning a corporate restructuring, the Wyeth integration, and the departure of senior staff in the R&D organization and oncology BU. The next year or so will tell whether Xalkori was a flash in the pan, or whether it marks the long awaited turnaround for Pfizer’s oncology business and a model for nimble drug development.

You may also be interested in...



Deals Of The Week: Value Surprise!

Sometimes the value of an asset is buried under serial acquisitions and doesn’t come to light for decades.. Also deal news from Janssen/GSK, Takeda/Immunomedics, Quintiles/Muscular Dystrophy Association, Vivus/Auxilium, Lilly/HMP, and Novartis/Immunogen

Epizyme Execs On Company’s IPO, Clinical Progress And Diagnostic Strategy

Epizyme and its partners have moved two programs into the clinic and will start an expansion trial for the DOT1L program later this year. It has also struck deals for companion diagnostics, making steady progress personalized medicine solutions for patients with genetically defined cancers within five years of starting clinical trials. CEO Robert Gould and Exec VP Jason Rhodes take stock of the company’s progress.

What’s Breakthrough Status Worth? Analysts Ask, But Companies Don’t Have Answers

Companies receiving breakthrough designations seem just as unclear as investors about the value of the program.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT125590

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel